Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Eur J Pharm Biopharm ; 198: 114249, 2024 May.
Article in English | MEDLINE | ID: mdl-38467334

ABSTRACT

In recent years, microneedles (MNs) have gained considerable interest in drug formulation due to their non-invasive and patient-friendly nature. Dissolving MNs have emerged as a promising approach to enhance drug delivery across the skin in a painless manner without generating sharp waste and providing the possibility for self-administration. Cyclodextrins, a group of cyclic oligosaccharides, are well-established in pharmaceutical products due to their safety and unique ability to form inclusion complexes with various drug molecules. In this manuscript, we report the development and characterization of dissolving MNs composed of cyclodextrins for intradermal delivery of a cyclodextrin-based nanoparticulate vaccine. Different cyclodextrins were tested and the most promising candidates were fabricated into MNs by micromolding. The MNs' piercing effectiveness and drug permeation across the skin were tested ex vivo. Furthermore, in vivo studies were carried out to assess the skin's tolerance to cyclodextrin-based MNs, and to evaluate the immune response using a model peptide antigen in a mouse model. The data revealed that the MNs were well-tolerated and effective, even leading to dose-sparing effects. This study highlights the potential of cyclodextrin-based dissolving MNs as a versatile platform for intradermal vaccine delivery, providing a compatible matrix for nanoparticulate formulations to enhance immune responses.


Subject(s)
Cyclodextrins , Nanoparticles , Vaccines , Mice , Animals , Humans , Nanovaccines , Skin , Drug Delivery Systems , Antigens , Peptides , Needles , Administration, Cutaneous
2.
J Antimicrob Chemother ; 79(4): 815-819, 2024 04 02.
Article in English | MEDLINE | ID: mdl-38334417

ABSTRACT

INTRODUCTION: Antimicrobial resistance in Neisseria gonorrhoeae compromises gonorrhoea treatment and rapid antimicrobial susceptibility testing (AST) would be valuable. We have developed a rapid and accurate flow cytometry method (FCM) for AST of gonococci. METHODS: The 2016 WHO gonococcal reference strains, and WHO Q, R and S (n = 17) were tested against seven clinically relevant antibiotics (ceftriaxone, cefixime, azithromycin, spectinomycin, ciprofloxacin, tetracycline and gentamicin). After 4.5 h incubation of inoculated broth, the fluorescent dye Syto™ 9 was added, followed by FCM analysis. After gating, the relative remaining population of gonococci, compared with unexposed growth control samples, was plotted against antimicrobial concentration, followed by non-linear curve regression analysis. Furthermore, the response at one single concentration/tested antibiotic was evaluated with the intention to use as a screening test for detection of resistant gonococci. RESULTS: A dose-dependent response was seen in susceptible isolates for all tested antimicrobials. There was a clear separation between susceptible/WT and resistant/non-WT isolates for ceftriaxone, cefixime, spectinomycin, ciprofloxacin and tetracycline. In contrast, for azithromycin, only high-level-resistant isolates were distinguished, while resistant isolates with MICs of 4 mg/L were indistinguishable from WT (MIC ≤ 1 mg/L) isolates. For gentamicin, all tested 17 isolates were WT and FCM analysis resulted in uniform dose-response curves. Using a single antibiotic concentration and a 50% remaining cell population cut-off, the overall sensitivity and specificity for resistance detection were 93% and 99%, respectively. CONCLUSIONS: By providing results in <5 h for gonococcal isolates, FCM-based AST can become a rapid screening method for antimicrobial resistance or antimicrobial susceptibility in gonococci.


Subject(s)
Anti-Infective Agents , Gonorrhea , Humans , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Neisseria gonorrhoeae , Azithromycin/pharmacology , Ceftriaxone/pharmacology , Spectinomycin/pharmacology , Cefixime/pharmacology , Flow Cytometry , Drug Resistance, Bacterial , Gonorrhea/epidemiology , Anti-Infective Agents/pharmacology , Ciprofloxacin/pharmacology , Tetracycline/pharmacology , Microbial Sensitivity Tests , Gentamicins/pharmacology
3.
Clin Otolaryngol ; 48(6): 895-901, 2023 11.
Article in English | MEDLINE | ID: mdl-37555629

ABSTRACT

OBJECTIVES: To investigate if prophylactic antibiotics (PA) in conjunction with myringoplasty of clean and uninfected ears entails a reduction of postoperative infections within 6 weeks after surgery, and whether it affects the healing rate of the tympanic membrane (TM) at follow-up, 6-24 months after surgery. DESIGN: A retrospective cohort study of prospectively collected data. SETTING: Data extracted from The Swedish Quality Register for Ear Surgery (SwedEar), the years 2013-2019. PARTICIPANTS: All patients in SwedEar with a registered clean conventional myringoplasty (tympanoplasty type I) including a follow-up visit. MAIN OUTCOME MEASURES: The effect of PA use on TM healing rate at follow-up and postoperative infection within 6 weeks of surgery. RESULTS: In the study group (n = 1665) 86.2% had a healed TM at follow-up. There was no significant difference between the groups that had PA administered (87.2%) or not (86.1%). A total of 8.0% had a postoperative infection within 6 weeks. Postoperative infection occurred in 10.2% of the group that received PA (n = 187) compared with 7.7% of the group that did not receive PA. However, this difference was not statistically significant. Postoperative infection within 6 weeks significantly lowered the frequency of healed TMs. CONCLUSION: PA administered during clean conventional myringoplasty does not improve the chance of having a healed TM at follow up, nor decrease the risk of having a postoperative infection within 6 weeks after surgery.


Subject(s)
Anti-Bacterial Agents , Myringoplasty , Surgical Wound Infection , Tympanic Membrane Perforation , Tympanic Membrane , Wound Healing , Humans , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis/statistics & numerical data , Cohort Studies , Myringoplasty/adverse effects , Myringoplasty/statistics & numerical data , Registries/statistics & numerical data , Retrospective Studies , Sweden/epidemiology , Treatment Outcome , Tympanic Membrane Perforation/drug therapy , Tympanic Membrane Perforation/epidemiology , Tympanic Membrane Perforation/surgery , Tympanic Membrane/drug effects , Tympanic Membrane/injuries , Tympanic Membrane/surgery , Follow-Up Studies , Surgical Wound Infection/epidemiology , Surgical Wound Infection/etiology , Surgical Wound Infection/prevention & control , Wound Healing/drug effects
4.
Vaccine ; 41(21): 3347-3357, 2023 05 16.
Article in English | MEDLINE | ID: mdl-37085452

ABSTRACT

The feared diarrheal disease cholera remains an important global health problem. Use of oral cholera vaccine (OCV) from a global stockpile against both epidemic and endemic cholera is a cornerstone in the World Health Organisations (WHOs) global program for "Ending cholera by 2030". Three liquid inactivated whole-cell OCVs (Dukoral®, ShancholTM, and Euvichol-Plus®) are WHO prequalified and have proved to be safe and effective. However, their multicomponent composition and cold-chain requirement increase manufacturing, storage and transport costs. ShancholTM and Euvichol-Plus® OCVs used in WHOs global vaccine stockpile also lack the protective cholera toxin B-subunit (CTB) antigen present in Dukoral®, which results in suboptimal efficacy. WHOs Global Task Force on Cholera Control (GTFCC) has identified a thermostable, dry formulation vaccine as a priority for further OCV development. We describe here the development of such a vaccine, based on a lyophilized mixture of a single strain of formalin-killed Hikojima bacteria together with a low-cost, recombinantly produced CTB. The new vaccine, which is easy and inexpensive to manufacture, could be stored for at least 26 months at 25 °C and for at least 8 months at 40 °C with preservation of cell morphology and with no loss of protective Ogawa and Inaba lipopolysaccharides or CTB. It also proved to be well tolerated and to have equivalent oral immunogenicity in mice as ShancholTM and Dukoral® OCVs with regard to both serum and intestinal-mucosal antibody responses.


Subject(s)
Cholera Vaccines , Cholera , Vibrio cholerae , Animals , Mice , Cholera Toxin , Cholera/prevention & control , Lipopolysaccharides , Administration, Oral , Vaccines, Inactivated
5.
Front Oncol ; 12: 1073457, 2022.
Article in English | MEDLINE | ID: mdl-36844924

ABSTRACT

Objectives: Immunotherapy by blocking programmed death protein-1 (PD-1) or programmed death protein-ligand1 (PD-L1) with antibodies (PD-1 blockade) has revolutionized treatment options for patients with non-small cell lung cancer (NSCLC). However, the benefit of immunotherapy is limited to a subset of patients. This study aimed to investigate the value of combining immune and genetic variables analyzed within 3-4 weeks after the start of PD-1 blockade therapy to predict long-term clinical response. Materials and methodology: Blood collected from patients with NSCLC were analyzed for changes in the frequency and concentration of immune cells using a clinical flow cytometry assay. Next-generation sequencing (NGS) was performed on DNA extracted from archival tumor biopsies of the same patients. Patients were categorized as clinical responders or non-responders based on the 9 months' assessment after the start of therapy. Results: We report a significant increase in the post-treatment frequency of activated effector memory CD4+ and CD8+ T-cells compared with pre-treatment levels in the blood. Baseline frequencies of B cells but not NK cells, T cells, or regulatory T cells were associated with the clinical response to PD-1 blockade. NGS of tumor tissues identified pathogenic or likely pathogenic mutations in tumor protein P53, Kirsten rat sarcoma virus, Kelch-like ECH-associated protein 1, neurogenic locus notch homolog protein 1, and serine/threonine kinase 11, primarily in the responder group. Finally, multivariate analysis of combined immune and genetic factors but neither alone, could discriminate between responders and non-responders. Conclusion: Combined analyses of select immune cell subsets and genetic mutations could predict early clinical responses to immunotherapy in patients with NSCLC and after validation, can guide clinical precision medicine efforts.

6.
PLoS One ; 8(12): e81865, 2013.
Article in English | MEDLINE | ID: mdl-24324726

ABSTRACT

Appropriate maintenance and regeneration of adult endocrine organs is important in both normal physiology and disease. We investigated cell proliferation, movement and differentiation in the adult mouse adrenal cortex, using different 5-bromo-2'-deoxyuridine (BrdU) labelling regimens and immunostaining for phenotypic steroidogenic cell markers. Pulse-labelling showed that cell division was largely confined to the outer cortex, with most cells moving inwards towards the medulla at around 13-20 µm per day, though a distinct labelled cell population remained in the outer 10% of the cortex. Pulse-chase-labelling coupled with phenotypic immunostaining showed that, unlike cells in the inner cortex, most BrdU-positive outer cortical cells did not express steroidogenic markers, while co-staining for BrdU and Ki67 revealed that some outer cortical BrdU-positive cells were induced to proliferate following acute adrenocorticotropic hormone (ACTH) treatment. Extended pulse-chase-labelling identified cells in the outer cortex which retained BrdU label for up to 18-23 weeks. Together, these observations are consistent with the location of both slow-cycling stem/progenitor and transiently amplifying cell populations in the outer cortex. Understanding the relationships between these distinct adrenocortical cell populations will be crucial to clarify mechanisms underpinning adrenocortical maintenance and long-term adaptation to pathophysiological states.


Subject(s)
Adrenal Cortex/cytology , Aging/metabolism , Cell Differentiation , Cell Movement , Adrenocorticotropic Hormone/pharmacology , Animals , Biomarkers/metabolism , Bromodeoxyuridine/metabolism , Cell Differentiation/drug effects , Cell Movement/drug effects , Cell Proliferation/drug effects , Injections , Mice , Mice, Inbred C57BL , Models, Biological , Staining and Labeling , Stem Cells/cytology , Stem Cells/drug effects , Stem Cells/metabolism , Steroids/metabolism
7.
J Clin Microbiol ; 51(6): 1779-85, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23554186

ABSTRACT

We report the characteristics of 115 extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli clinical isolates, from 115 unique Danish patients, over a 1-year study interval (1 October 2008 to 30 September 2009). Forty-four (38%) of the ESBL isolates represented sequence type 131 (ST13)1, from phylogenetic group B2. The remaining 71 isolates were from phylogenetic groups D (27%), A (22%), B1 (10%), and B2 (3%). Serogroup O25 ST131 isolates (n = 42; 95% of ST131) comprised 7 different K antigens, whereas two ST131 isolates were O16:K100:H5. Compared to non-ST131 isolates, ST131 isolates were associated positively with CTX-M-15 and negatively with CTX-M-1 and CTX-M-14. They also were associated positively with 11 virulence genes, including afa and dra (Dr family adhesins), the F10 papA allele (P fimbria variant), fimH (type 1 fimbriae), fyuA (yersiniabactin receptor), iha (adhesin siderophore), iutA (aerobactin receptor), kpsM II (group 2 capsules), malX (pathogenicity island marker), ompT (outer membrane protease), sat (secreted autotransporter toxin), and usp (uropathogenicity-specific protein) and negatively with hra (heat-resistant agglutinin) and iroN (salmochelin receptor). The consensus virulence gene profile (>90% prevalence) of the ST131 isolates included fimH, fyuA, malX, and usp (100% each), ompT and the F10 papA allele (95% each), and kpsM II and iutA (93% each). ST131 isolates were also positively associated with community acquisition, extraintestinal pathogenic E. coli (ExPEC) status, and the O25, K100, and H4 antigens. Thus, among ESBL E. coli isolates in Copenhagen, ST131 was the most prevalent clonal group, was community associated, and exhibited distinctive and comparatively extensive virulence profiles, plus a greater variety of capsular antigens than reported previously.


Subject(s)
Epidemics , Escherichia coli Infections/epidemiology , Escherichia coli Infections/microbiology , Escherichia coli/classification , Escherichia coli/genetics , beta-Lactamases/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Denmark/epidemiology , Escherichia coli/enzymology , Escherichia coli/isolation & purification , Female , Genotype , Humans , Infant , Male , Middle Aged , Molecular Epidemiology , Prevalence , Serotyping , Virulence Factors/genetics , Young Adult
8.
Anal Bioanal Chem ; 385(8): 1421-9, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16804672

ABSTRACT

In this work, a real-time sampling/analytical method for on-line measurements of two newly discovered cyclomaltodextrinases (CDases) has been developed and evaluated. This novel methodology not only allows the final products to be investigated, but it also reveals enzyme-specific differences in the degradation pathways during the hydrolysis of different substrates, which is a great advantage in the important tasks of investigating the mechanisms of and classifying new hydrolases, and is an advantage that conventional techniques cannot offer. Two different enzymes, one CDase from Laceyella sacchari (LsCda13) and one from Anoxybacillus flavithermus (AfCda13), were investigated during the hydrolysis of alpha-, beta- and gamma-cyclodextrin, and the hydrolysis products were sampled via a microdialysis probe and injected on-line every 30 min into a high-performance anion exchange chromatography system equipped with a pulsed amperometric detector (HPAEC-PAD), where they were identified. The enzymes yielded the same end-products, maltose and glucose, in an approximate molar ratio of 2:1, but they exhibited distinctly different patterns of intermediate product formation before reaching the end-point. LsCda13 had a more random distribution of the intermediate products, whereas AfCda13 showed the distinct intermediate production of maltotriose, which in some cases accumulated.


Subject(s)
Chromatography, High Pressure Liquid/methods , Chromatography, Ion Exchange/methods , Glycoside Hydrolases/metabolism , Microdialysis/methods , Anion Exchange Resins/chemistry , Buffers , Cyclodextrins/metabolism , Hydrolysis
9.
Med Eng Phys ; 28(8): 802-8, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16442328

ABSTRACT

By recognizing and characterizing conditions under which atrial fibrillation (AF) is likely to terminate spontaneously or be sustained, improved treatment of sustained AF may result and unnecessary treatment of self-terminating AF avoided. Time-frequency measures that characterize AF, such as fibrillatory frequency, amplitude, and waveform shape (exponential decay), are extracted from the residual ECG following QRST cancellation. Three complexity measures are also studied, characterizing the degree of organization of atrial activity. All measures are analysed using a training set, consisting of 20 recordings of AF with known termination properties, and a test set of 30 recordings. Spontaneous termination was best predicted by a low and stable fibrillatory frequency and a low exponential decay. Using these predictors, 90% of the test set was correctly classified into terminating and sustained AF. Neither fibrillation amplitude nor the complexity measures differed significantly between the two sets.


Subject(s)
Algorithms , Artificial Intelligence , Atrial Fibrillation/diagnosis , Atrial Fibrillation/physiopathology , Diagnosis, Computer-Assisted/methods , Electrocardiography/methods , Risk Assessment/methods , Humans , Pattern Recognition, Automated/methods , Prognosis , Reproducibility of Results , Risk Factors , Sensitivity and Specificity
10.
Conf Proc IEEE Eng Med Biol Soc ; 2006: 1406-9, 2006.
Article in English | MEDLINE | ID: mdl-17945643

ABSTRACT

A Hidden Markov Model (HMM) is used to improve the robustness to noise when tracking the atrial fibrillation (AF) frequency in the ECG. Each frequency interval corresponds to a state in the HMM. Following QRST cancellation, a sequence of observed states is obtained from the residual ECG, using the short time Fourier transform. Based on the observed state sequence, the Viterbi algorithm, which uses a state transition matrix, an observation matrix and an initial state vector, is employed to obtain the optimal state sequence. The state transition matrix incorporates knowledge of intrinsic AF characteristics, e.g., frequency variability, while the observation matrix incorporates knowledge of the frequency estimation method and SNRs. An evaluation is performed using simulated AF signals where noise obtained from ECG recordings have been added at different SNR. The results show that the use of HMM considerably reduces the average RMS error associated with the frequency tracking: at 5 dB SNR the RMS error drops from 1.2 Hz to 0.2 Hz.


Subject(s)
Atrial Fibrillation/diagnosis , Atrial Fibrillation/physiopathology , Diagnosis, Computer-Assisted/methods , Electrocardiography/methods , Heart Rate , Markov Chains , Pattern Recognition, Automated/methods , Humans , Models, Cardiovascular , Models, Statistical , Reproducibility of Results , Sensitivity and Specificity , Signal Processing, Computer-Assisted
SELECTION OF CITATIONS
SEARCH DETAIL